Cisen Pharmaceutical Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100002VG4
  • SHG: 603367
CNY
14.60
0.14 (0.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore

Dashboard

1

Poor Management Efficiency with a low ROCE of 11.05%

  • The company has been able to generate a Return on Capital Employed (avg) of 11.05% signifying low profitability per unit of total capital (equity and debt)
2

The company is Net-Debt Free

3

Poor long term growth as Net Sales has grown by an annual rate of -1.89% and Operating profit at -5.50% over the last 5 years

 
4

Flat results in Jun 26

5

With ROE of 6.32%, it has a attractive valuation with a 0.89 Price to Book Value

6

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 6,745 Million (Mid Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.32%

stock-summary
Debt Equity

-0.47

stock-summary
Return on Equity

6.32%

stock-summary
Price to Book

1.07

Revenue and Profits:
Net Sales:
843 Million
(Quarterly Results - Jun 2026)
Net Profit:
135 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.11%
0%
11.11%
6 Months
-9.43%
0%
-9.43%
1 Year
-30.54%
0%
-30.54%
2 Years
23.42%
0%
23.42%
3 Years
8.87%
0%
8.87%
4 Years
26.19%
0%
26.19%
5 Years
12.22%
0%
12.22%

Cisen Pharmaceutical Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-1.89%
EBIT Growth (5y)
-5.50%
EBIT to Interest (avg)
94.29
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.62
Tax Ratio
13.94%
Dividend Payout Ratio
37.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.17%
ROE (avg)
7.85%

Valuation key factors

Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.89
EV to EBIT
10.29
EV to EBITDA
6.41
EV to Capital Employed
0.79
EV to Sales
0.79
PEG Ratio
NA
Dividend Yield
2.78%
ROCE (Latest)
7.72%
ROE (Latest)
6.32%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 2.83% vs -9.95% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 55.48% vs -22.24% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "842.80",
          "val2": "819.60",
          "chgp": "2.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "71.10",
          "val2": "105.20",
          "chgp": "-32.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "44.00",
          "val2": "15.50",
          "chgp": "183.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "134.80",
          "val2": "86.70",
          "chgp": "55.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.80%",
          "val2": "72.50%",
          "chgp": "-5.17%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -13.50% vs -10.64% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -17.34% vs -2.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,419.90",
          "val2": "3,953.80",
          "chgp": "-13.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "457.70",
          "val2": "638.70",
          "chgp": "-28.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "7.60",
          "chgp": "-77.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "39.70",
          "val2": "10.50",
          "chgp": "278.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "425.60",
          "val2": "514.90",
          "chgp": "-17.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "74.90%",
          "val2": "104.60%",
          "chgp": "-2.97%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - YoYstock-summary

Jun'26
Jun'25
Change(%)
Net Sales
842.80
819.60
2.83%
Operating Profit (PBDIT) excl Other Income
71.10
105.20
-32.41%
Interest
0.10
0.40
-75.00%
Exceptional Items
44.00
15.50
183.87%
Consolidate Net Profit
134.80
86.70
55.48%
Operating Profit Margin (Excl OI)
20.80%
72.50%
-5.17%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2026 is 2.83% vs -9.95% in Jun 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2026 is 55.48% vs -22.24% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
3,419.90
3,953.80
-13.50%
Operating Profit (PBDIT) excl Other Income
457.70
638.70
-28.34%
Interest
1.70
7.60
-77.63%
Exceptional Items
39.70
10.50
278.10%
Consolidate Net Profit
425.60
514.90
-17.34%
Operating Profit Margin (Excl OI)
74.90%
104.60%
-2.97%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -13.50% vs -10.64% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -17.34% vs -2.00% in Dec 2024

stock-summaryCompany CV
About Cisen Pharmaceutical Ltd. stock-summary
stock-summary
Cisen Pharmaceutical Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Footer loading